FMP
Midatech Pharma plc
MTP
NASDAQ
Inactive Equity
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
0.285 USD
-0.0647 (-22.69%)
Historical Prices
From:
To:
About
ceo
Mr. Stephen A. Stamp
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer ...
CIK
0001643918
ISIN
US59564R7089
CUSIP
59564R104
Address
1 Caspian Point
Phone
44 29 2048 0180
Country
GB
Employee
20
IPO Date
Dec 7, 2015
Financial Statement
Earnings
MTP Financial Summary
CIK
0001643918
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
59564R104
ISIN
US59564R7089
Country
GB
Price
0.29
Beta
1.22
Volume Avg.
1.84M
Market Cap
1.98M
Shares
-
52-Week
0.19-20.8
DCF
2.21
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.14
P/B
-
Website
https://www.midatechpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MTP News
InvestorPlace
Mar 28, 2023
Why Is Midatech Pharma (BDRX) Stock Up 64% Today?
Midatech Pharma (NASDAQ: BDRX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program. According to a filing with the Securities and Exchange Commission (SEC).
Proactive Investors
Dec 14, 2022
Midatech Pharma plc continues to plummet on news of London d...
Midatech Pharma PLC (AIM:MTPH) fell another 13% to 3p on Wednesday, having now slashed its market valuation by half in the past five days. A day earlier, Midatech announced the proposed acquisition of Canada-listed Bioasis Technologies Inc for C$7.4mln (£4.4mln).
Proactive Investors
Jun 21, 2022
Midatech Pharma boosted by European news on key product
Midatech Pharma PLC (AIM:MTPH) is in demand after a positive European approval for a key product. The biotechnology company said that the European Medicines Agency had granted orphan medicinal product designation for its development programme of MTX110 for the treatment of glioma Midatech has been developing MTX110 for the treatment of recurrent glioblastoma ("rGBM") in adult patients and diffuse intrinsic pontine glioma ("DIPG") and medulloblastoma in paediatric patients.
Benzinga
Jun 1, 2022
Midatech Pharma's Shares Shoot Higher On FDA Fast Track Desi...
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Midatech Pharma PLC's (NASDAQ: MTP) lead drug candidate MTX110 for the treatment of patients with recurrent glioblastoma (rGBM). The company is planning to begin recruitment in the phase 1 study evaluating MTX110.
Seeking Alpha
Sep 20, 2021
Midatech Pharma plc (MTP) CEO Stephen Stamp on Q2 2021 Resul...
Midatech Pharma plc (MTP) CEO Stephen Stamp on Q2 2021 Results - Earnings Call Transcript
Accesswire
Sep 6, 2021
Midatech Pharma PLC Announces Notice of Interim Results
ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 6, 2021 / Midatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it will release its interim results for the six months ended 30 June 2021 at 7.00 am BST on Friday 17 September 2021. The Company will be hosting a webinar at 5.30pm BST / 12.30pm EST on Monday 20 September 2021.
Benzinga
Jun 29, 2021
Midatech Pharma Secures £10M In Equity To Fund Product Devel...
Midatech Pharma plc (NASDAQ: MTP) has raised £10 million from equity placing to fund its product development pipeline. Approximately 35 million new shares in the Company were issued at 28.5p each, a 12% discount on Monday's closing price.
InvestorPlace
Jun 17, 2021
MTP Stock: The Big Midatech Pharma News That Has Shares Rock...
Shares of MTP stock are skyrocketing on Thursday following news of positive results from a portion of Midatech Pharma's technology. The post MTP Stock: The Big Midatech Pharma News That Has Shares Rocketing Today appeared first on InvestorPlace.
